NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State University has been added as a new clinical site in the ongoing Phase 1 trial of the Company’s INB-100, a donor-derived allogeneic gamma-delta T cell therapy for patients with leukemias undergoing haploidentical stem cell transplantation. The addition of this leading acade ...

Core Points - Rio2 Limited provides an update on the Fenix Gold Project, which is 63% complete and on track for first gold production in January 2026 [1][3] Construction Progress - As of Q3 2025, a total of 1,865,791 person-hours have been worked with a Lost Time Incident Frequency Rate (LTIFR) of 1.61 and a Total Incident Frequency Rate (TIFR) of 8.58 [2] - Total expenditure since November 2024 is $86.7 million, slightly above the budget of $86.6 million [3] - 12.7 hectares of geosynthetics have been installed on the leach pad, ensuring six months of production capacity [4] - Mining of ore began in August, with 87,000 tonnes of ore placed on the leach pad at an average gold grade of 0.45 g/t, equating to 1,260 ounces [5] Infrastructure Development - The Pregnant Leach Solution (PLS) pond is complete and ready for hydrostatic testing, with water trucking initiated to fill the pond by mid-November [6] - Haul Road 1 is complete, and Haul Road 4 is largely finished [6] - Key components of the Adsorption, Desorption, Recovery (ADR) Plant have been installed, including diesel generators and reactors for chemical reactivation [7] Human Resources - The project currently employs 1,521 personnel, with 94% being Chileans, 44% from the Atacama Region, and 13% female [8] Exploration and Resource Management - Grade control drilling at Fenix South was completed in July, with preliminary analysis indicating close reconciliation of the grade control model to the reserve model [9] Future Milestones - Upcoming milestones include filling the PLS pond, leach process commissioning in November, plant commissioning in December/January, and the first gold pour in January 2026 [15]

The largest local REALTOR® Association in the state of Utah contracts to make FOREWARN services available for its 9,000+ real estate professional members to promote proactive agent safetyBOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- FOREWARN, LLC, a red violet company (NASDAQ: RDVT) and the leading provider of real-time information solutions for real estate agents, today announced that Salt Lake Board of REALTORS® will offer FOREWARN® services to its 9,000+ members it serves throughout Salt Lake City ...

BENTONVILLE, Ark., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) today announced a further strengthening of its Board of Directors with the appointment of Christopher J. Jemapete, effective today. Mr. Jemapete was an early strategic investor in Glucose Health, Inc. beginning in 2017 and continues to maintain a substantial equity position in the company. Mr. Jemapete brings three decades of experience in the financial services and securities industry to the Board of Directors of Glucose ...

Core Viewpoint - Lead Real Estate Co., Ltd (LRE) is set to release its financial results for the fiscal year ended June 30, 2025, on November 3, 2025, before the U.S. market opens, followed by a conference call to discuss the results and outlook [1]. Company Overview - Lead Real Estate Co., Ltd is a Japanese developer specializing in luxury residential properties, including single-family homes and condominiums in Tokyo, Kanagawa Prefecture, and Sapporo [3]. - The company also operates the ENT TERRACE brand of extended-stay hotels and leases apartment units in Japan and Dallas, Texas [3]. Mission and Strategy - The company's mission is to provide stylish, safe, and luxurious living, guided by the philosophy of Kaizen (continuous improvement) to enhance operational efficiency [4]. - LRE aims to expand its award-winning luxury housing and hotel portfolio while building a global real-estate transaction platform that offers access to prime properties in Japan and internationally, including the U.S. and Hong Kong [4]. Conference Call Details - The conference call to discuss the fiscal year 2025 earnings will take place on November 3, 2025, at 8:30 AM Eastern Time (10:30 PM Japan Standard Time) [2]. - Participants can join the call via a toll-free number in the U.S. or an international dial-in number, with a conference ID provided for access [2].

Los Angeles, California, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Linkhome Holdings Inc. (Nasdaq: LHAI), a leading AI-powered real estate technology company, today announced that its wholly owned subsidiary, Linkhome AI, Inc., has entered into a strategic partnership agreement with Beike Realsee Technology (HK) Limited, one of China’s largest and most advanced real estate technology platforms and the backbone of KE Holdings Inc. (NYSE: BEKE)’s 3D virtual-tour property viewing solution. Under the agreement, the two ...

Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to discover and develop multispecific antibodies for several therapeutic indications of mutual intere ...

Core Points - Ekso Bionics Holdings, Inc. has entered into a definitive agreement for the purchase and sale of 769,490 shares of common stock at a price of $4.81 per share, expected to close around October 30, 2025 [1] - The gross proceeds from this offering are anticipated to be $3.7 million, which will be used for general corporate purposes including research and development, administrative costs, and working capital needs [3] - The shares are being offered under a "shelf" registration statement previously filed with the SEC, and the offering will be conducted via a prospectus [4] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility for both medical and industrial applications [6] - The company focuses on improving health and quality of life through advanced robotics, and is recognized for its unique technologies that assist individuals with paralysis and enhance capabilities in various job sites [6] - Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [6]

Core Viewpoint - China Harbour International Financial Limited successfully assisted SIGUWORKS in the tokenization and issuance of real world assets (RWA) for its IP brand Puff Koala, marking a significant development in the digital finance sector [1][3]. Group 1: Project Overview - The RWA issuance project is designed around KOALA's IP licensing income rights in Southeast Asia, North America, and Europe, utilizing blockchain technology for tokenization [3]. - The total size of the issuance is in the tens of millions of US dollars, making it the largest IP RWA project in recent times [4]. - The project employs an offshore special purpose vehicle (SPV) structure, with cash flow from underlying assets distributed to token holders via smart contracts, ensuring transparency and automation in profit distribution [4]. Group 2: Company Expertise - China Harbour International specializes in digital financial investment banking and holds multiple licenses from the Securities and Futures Commission of Hong Kong, enabling various financial services [5]. - The company offers comprehensive services in RWA issuance, including asset screening, structural design, legal compliance, and technical implementation, while maintaining close cooperation with leading industry institutions [5]. - China Harbour International has a deep understanding of global regulatory requirements, allowing it to design optimal cross-border issuance solutions for clients [5]. Group 3: Technical Capabilities - The company has developed an asset chain platform with independent intellectual property rights to ensure the authenticity and integrity of underlying asset data [6]. - The platform utilizes IoT devices to collect real-time asset operation data, providing investors with a transparent asset monitoring experience [6].

Core Insights - Purple Biotech has achieved a commercially viable yield for IM1240, a tri-specific antibody targeting the tumor-associated antigen 5T4, positioning the program competitively for future development [1] - The CAPTN-3 platform has been validated for scalability, indicating its potential for developing complex tri-specific antibodies with competitive yield and purity [2] Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance, with a pipeline that includes CAPTN-3, CM24, and NT219 [3] - IM1240 is the first tri-specific antibody in development targeting the 5T4 antigen, which is associated with advanced disease and poor clinical outcomes in various solid tumors [3] Technology and Mechanism - The CAPTN-3 platform generates conditionally activated tri-specific antibodies that engage both T cells and NK cells, inducing a strong localized immune response within the tumor microenvironment [2][3] - The technology incorporates a cleavable capping mechanism that confines therapeutic activity to the tumor microenvironment, potentially increasing the therapeutic window for patients [2][3] Clinical Development - An Investigational New Drug (IND) submission for IM1240 is planned for 2026, with the antibody advancing toward first-in-human clinical trials [1] - NT219 has demonstrated anti-tumor activity in combination with cetuximab in a Phase 1 study and is currently being evaluated in a Phase 2 study for recurrent and/or metastatic squamous cell carcinoma of the head and neck [4]